olezarsen: Clinical Trials

11 trials of olezarsen, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 completed, 3 active not recruiting, 1 approved for marketing, 1 recruiting. 8 Phase 3, 1 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	8	Completed 4, Active not recruiting 3, Recruiting 1
Phase 1	1	Completed 1
Phase 2	1	Completed 1

Follow olezarsen: new trials by email Literature Review of olezarsen trials Research Report on olezarsen

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants Olezarsen - Familial Chylomicronemia Syndrome	Phase 3	Recruiting	Ionis Pharmaceuticals, Inc.	12	2026-07-31	2026-10-08
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) Olezarsen - Severe Hypertriglyceridemia	Phase 3	Active not recruiting	Ionis Pharmaceuticals, Inc.	885	2022-12-13	2025-12-01
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia Olezarsen, Placebo - Hypertriglyceridemia, Cardiovascular Diseases	Phase 3	Completed	Ionis Pharmaceuticals, Inc.	1478	2022-11-21	2026-02-10
A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants Olezarsen - Healthy Participants	Phase 1	Completed	Ionis Pharmaceuticals, Inc.	104	2022-10-05	2024-05-10
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia	Phase 3	Completed	Ionis Pharmaceuticals, Inc.	446	2022-08-31	2025-10-22
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia Olezarsen, Placebo - Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease	Phase 2	Completed	Ionis Pharmaceuticals, Inc.	154	2022-05-09	2026-04-23
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen Olezarsen - Familial Chylomicronemia Syndrome	Phase 3	Active not recruiting	Ionis Pharmaceuticals, Inc.	24	2022-02-25	2025-12-12
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) Olezarsen - Familial Chylomicronemia Syndrome	Phase 3	Active not recruiting	Ionis Pharmaceuticals, Inc.	60	2021-11-18	2025-12-12
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia	Phase 3	Completed	Ionis Pharmaceuticals, Inc.	617	2021-10-25	2026-02-10
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) Olezarsen, Placebo - Familial Chylomicronemia Syndrome	Phase 3	Completed	Ionis Pharmaceuticals, Inc.	66	2020-11-18	2025-03-06
Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS) Olezarsen - Familial Chylomicronemia Syndrome		Approved for marketing	Ionis Pharmaceuticals, Inc.			2024-12-27

Conditions studied

Sponsors

Countries

Results publications

NIH funding